CRISPR Therapeutics AG (CRSP) SEC 13F Holdings (Q2 2026) — Net Institutional Activity: $283.0M

CRSP ranks #1101 out of 37696 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

CRSP is a disclosed holding of Cathie Wood (ARK Investment Management), one of the tracked superinvestors on AlphaSMO — it makes up 3.4% of that fund's own 13F portfolio.

CRSP is a top-conviction position for GSK plc — at 29.2% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in CRSP belongs to ARK Investment Management LLC, but the position matters far more to GSK plc, who has 29.2% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

Concurrent Investment Advisors, LLC has added to its CRSP position for two straight quarters, increasing it by $3.8M to reach $6.8M today.

Wealth Enhancement Trust Services, Inc. has trimmed its CRSP position for two straight quarters, cutting it by $736.5K while still holding $1.1M.

CRSP is down 4.4% today, but institutions show net buying of $283.0M this quarter — a divergence between today's price move and the underlying institutional flow.

CRSP reported a net loss of $451.1M over the trailing twelve months.

• Not yet profitable — net loss of $451.1M over the trailing twelve months
• Revenue declined 64.8% year over year
• Net income improved year over year, from -$467.8M to -$451.1M
• Operating cash flow was negative, using $345.0M in cash
• Current ratio of 13.32x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.18x equity — within a conventional range